TrialVaccine2021

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Patricia Winokur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.